المؤلفون: Broyelle, Antonin, Delanoy, Nicolas, Bimbai, André-Michel, Le Deley, Marie-Cécile, Penel, Nicolas, Villers, Arnauld, Lebellec, Loïc, Oudard, Stéphane

المصدر: Clinical Genitourinary Cancer; Jun2023, Vol. 21 Issue 3, p349-356, 10p

مصطلحات موضوعية: ANDROGEN receptors, CASTRATION-resistant prostate cancer, ABIRATERONE acetate, PROGRESSION-free survival, DOCETAXEL

المؤلفون: Hu, Jason, Aprikian, Armen G., Vanhuyse, Marie, Dragomir, Alice

المصدر: Clinical Genitourinary Cancer; Feb2022, Vol. 20 Issue 1, p17-24, 8p

مصطلحات موضوعية: CASTRATION-resistant prostate cancer, METASTASIS, CARDIOVASCULAR diseases risk factors, CARDIOTOXICITY, ADVERSE health care events, ABIRATERONE acetate

المؤلفون: Neal D. Shore, Louise Yu, Dominique Lejeune, S. Ghate, François Laliberté, Jeri Kim, Lingfeng Yang, Mei Sheng Duh, Malena Mahendran, Raluca Ionescu-Ittu

المصدر: Clinical Genitourinary Cancer. 19:480-490

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Urology, Population, Abiraterone Acetate, chemistry.chemical_compound, Prostate cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, medicine, Overall survival, Humans, Enzalutamide, education, Aged, Retrospective Studies, education.field_of_study, business.industry, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Abiraterone, Treatment Outcome, Docetaxel, chemistry, Benzamides, Cohort, Adenocarcinoma, Androstenes, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252e95e2e33b1d2fa1e60ab272f63ac8Test
https://doi.org/10.1016/j.clgc.2021.07.009Test

المؤلفون: Lucie-Marie SCAILTEUX, Sébastien VINCENDEAU, Gwenaëlle GRAVIS, Romain MATHIEU, Frédéric BALUSSON, Sandrine KERBRAT, Emmanuel OGER

المساهمون: École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Sud [CHU Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Privé Saint-Grégoire [Saint-Gregoire] (CHPSG - Bretagne), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), This work was supported by French National Agency for the Safety of Medicines and Health Products (Agence Nationale de Sécurité du Médicament et des produits de santé, 'ANSM'), as part of the ‘Pharmaco-Epidémiologie des Produits de Santé’ consortium research program.

المصدر: Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, 2023, ⟨10.1016/j.clgc.2023.04.004⟩

مصطلحات موضوعية: Oncology, Urology, Sequence, Enzalutamide, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Abiraterone, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Comorbidities, Treatment patterns

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7ae16989350721808c2c588b5b4a31dTest
https://doi.org/10.1016/j.clgc.2023.04.004Test

المؤلفون: Stéphane Oudard, François Kleinclauss, Rémi Pelloux-Prayer, Antoine Thiery-Vuillemin, Philomène Schiele, Lionel Geoffrois, Samuel Limat, Gilles Créhange, Gwenaelle Gravis, Alicia K. Morgans, Christophe Hennequin, Virginie Nerich

المصدر: Web of Science

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Cost-Benefit Analysis, Urology, Abiraterone Acetate, 030232 urology & nephrology, Docetaxel, law.invention, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Randomized controlled trial, Prednisone, law, Internal medicine, medicine, Humans, Enzalutamide, Neoplasm Metastasis, Randomized Controlled Trials as Topic, business.industry, Therapies, Investigational, Abiraterone acetate, Prostatic Neoplasms, Cost-effectiveness analysis, medicine.disease, Hormones, Markov Chains, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Cohort, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798ce2836e7f49baf13623d7c9b81f4cTest
https://doi.org/10.1016/j.clgc.2021.03.022Test

المؤلفون: Shigeto Ishidoya, Masanori Ishida, Shintaro Narita, Chikara Ohyama, Kazutaka Okita, Akihiro Ito, Jiro Shimoda, Toshiaki Kawaguchi, Koji Mitsuzuka, Shingo Hatakeyama, Senji Hoshi, Hiromi Sato, Sadafumi Kawamura, Norihiko Tsuchiya, Tomonori Habuchi, Masahiro Takahashi, Toshihiko Sakurai, Yoichi Arai

المصدر: Clinical Genitourinary Cancer. 18:e103-e111

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Urology, Abiraterone Acetate, 030232 urology & nephrology, Docetaxel, Kaplan-Meier Estimate, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, Androgen Receptor Antagonists, medicine, Humans, Enzalutamide, Aged, Retrospective Studies, Proportional hazards model, business.industry, Hazard ratio, Abiraterone acetate, Prostate-Specific Antigen, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, chemistry, Cabazitaxel, 030220 oncology & carcinogenesis, Benzamides, Kallikreins, Taxoids, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a664334915df21a666c7e82c55a8f2acTest
https://doi.org/10.1016/j.clgc.2019.09.006Test

المؤلفون: Alice Dragomir, Armen Aprikian, M. Vanhuyse, Jason Hu

المصدر: Clinical genitourinary cancer. 20(1)

مصطلحات موضوعية: Male, medicine.medical_specialty, Acute coronary syndrome, Urology, Population, Abiraterone Acetate, chemistry.chemical_compound, Internal medicine, Nitriles, medicine, Enzalutamide, Humans, education, Adverse effect, Proportional Hazards Models, Retrospective Studies, Heart Failure, education.field_of_study, business.industry, Abiraterone acetate, medicine.disease, Clinical trial, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Oncology, chemistry, Cohort, Propensity score matching, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58954cbe8ec9a6b1baf59665ac668b6Test
https://pubmed.ncbi.nlm.nih.gov/34706850Test

المؤلفون: Shusuke Akamatsu, Osamu Ogawa, Naoki Terada, Takahiro Kimura, Yumi Fujimoto, Takahiro Inoue, Nobuaki Matsubara, Takashi Kobayashi, Keiichiro Mori, Kaoru Murakami

المصدر: Clinical Genitourinary Cancer. 18:e46-e54

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Urology, medicine.medical_treatment, Abiraterone Acetate, 030232 urology & nephrology, urologic and male genital diseases, Tosyl Compounds, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, Androgen Receptor Antagonists, medicine, Humans, Enzalutamide, Anilides, Progression-free survival, Aged, Aged, 80 and over, Chemotherapy, business.industry, Hazard ratio, Middle Aged, Prostate-Specific Antigen, medicine.disease, Flutamide, Progression-Free Survival, Confidence interval, Androgen receptor, Prostatic Neoplasms, Castration-Resistant, chemistry, Receptors, Androgen, 030220 oncology & carcinogenesis, Benzamides, Toxicity, Kallikreins, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5091cb88867b170af140fadcdd0d1dbTest
https://doi.org/10.1016/j.clgc.2019.09.011Test

المؤلفون: Ryota Aki, Daisuke Motoyama, Hideaki Miyake, Atsushi Otsuka, Takayuki Sugiyama, Keita Tamura, Toshiki Ito, Yuto Matsushita

المصدر: Clinical Genitourinary Cancer. 16:219-225

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, medicine.drug_class, Urology, Abiraterone Acetate, 030232 urology & nephrology, Docetaxel, Castration resistant, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Japan, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, medicine, Humans, Enzalutamide, Aged, Aged, 80 and over, business.industry, Abiraterone acetate, Middle Aged, Prostate-Specific Antigen, medicine.disease, Androgen, Survival Analysis, Progression-Free Survival, Clinical Practice, Androgen receptor, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Benzamides, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6af3c07e6ac31fd9e8cf5645abcba8eTest
https://doi.org/10.1016/j.clgc.2017.11.007Test

المؤلفون: Steven Yip, Mary-Ellen Taplin, Anthony M. Joshua, Daniel Y.C. Heng, Grace Shaw, Christopher Sweeney, Edoardo Francini, Haocheng Li, Shubidito Ahmed, Luke Ardolino, Philip W. Kantoff, Nimira S. Alimohamed, Marina D. Kaymakcalan, Carolyn Evan

المصدر: Clinical Genitourinary Cancer. 16:130-134

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, medicine.drug_class, Urology, Abiraterone Acetate, Docetaxel, Disease-Free Survival, Article, law.invention, Androgen deprivation therapy, Efficacy, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, medicine, Humans, Enzalutamide, 030212 general & internal medicine, Retrospective Studies, business.industry, Abiraterone acetate, AR targeting agents, CHAARTED, mCRPC, mCRPC sequencing, mHSPC, Prostatic Neoplasms, Castration-Resistant, Survival Analysis, Treatment Outcome, medicine.disease, Androgen, chemistry, 030220 oncology & carcinogenesis, Benzamides, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0825a93efc9694ab8f68316b7bc258bcTest
https://doi.org/10.1016/j.clgc.2017.12.012Test